Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
Rivals Novartis and Amgen are already in Phase III with Lp(a) drugs
Executive Summary
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.